March 11 (Reuters) - Bristol Myers Squibb (BMY.N), opens new tab will acquire 2seventy bio (TSVT.O), opens new tab for about $286 million in cash, sending the cancer cell therapy maker's shares up ...

By acquiring 2Seventy Bio, Bristol eliminates its obligation to pay royalties on sales of Abecma, a personalized CAR-T therapy for multiple myeloma. 2Seventy was once part of cell and gene therapy ...

With a female governor and deputy governor running HMP Bristol for the first time in its 141-year history, Jade said she was given the support to climb the ranks quickly since joining the service ...

It was revealed Monday that Pharma giant Bristol-Myers Squibb will acquire ... helped develop the first FDA-approved CAR T cell therapy for multiple myeloma, Abecma. Abecma was once considered ...

Bristol Myers Squibb is acquiring 2seventy bio, a deal that gives the pharmaceutical giant full control over the partnered cancer cell therapy Abecma as that product faces headwinds in a ...

More than a year into a strategic pivot to zero in on the multiple myeloma cell therapy Abecma, 2seventy bio is selling itself to partner Bristol Myers Squibb. Bristol Myers has agreed to buy out ...

2seventy bio, the cell therapy spinout of Bluebird bio, is selling itself to Bristol Myers Squibb after losing most of its market value in its short run as an independent biotechnology company.